Mazdutide: What It Is, Results, Side Effects, FDA Status
Mazdutide is a once-weekly shot that acts on two receptors, GLP-1 and glucagon. It is approved in China for weight management and type 2 diabetes, and on November 13, 2026 Innovent said it will join China's national insurance drug list for type 2 diabetes from January 1, 2027. It is not FDA approved and no US filing has been announced. In trials people lost about 14% of their weight at 48 weeks on 6 mg and about 17% at 60 weeks on 9 mg. On any drug this strong, protein and strength work protect your muscle, and Sharpy gives you one protein target and one 20-minute workout a day.
What is mazdutide? Mazdutide is a once-weekly shot for weight loss and type 2 diabetes. It acts on two hormone receptors: GLP-1 and glucagon. It is approved in China, where Innovent Biologics sells it. It is not approved by the FDA, and you cannot get it legally in the United States outside a clinical trial.
It is in the news this week. On November 13, 2026, Innovent said mazdutide made China's 2026 National Reimbursement Drug List for the first time.
What is mazdutide used for?
China's drug regulator, the NMPA, approved mazdutide on June 27, 2025 for long-term weight management. It is for adults with a BMI of 28 or more, or 24 or more with at least one weight-related health problem, used with diet and exercise. Later in 2025 it was also approved for blood sugar control in adults with type 2 diabetes.
You may see it under other names. Lilly's code is LY3305677 or OXM3. Innovent's code is IBI362. Trade listings give the Chinese brand name as Xinermei.
How does the mazdutide peptide work?
Mazdutide is a peptide built to act like oxyntomodulin, a hormone your gut makes after meals. It switches on two receptors:
- GLP-1. The same target as Ozempic and Wegovy. It lowers appetite and helps control blood sugar.
- Glucagon. The idea is that this adds extra calorie burn and helps the liver clear fat.
That makes it a cousin of survodutide, which hits the same two targets. Zepbound uses a different pair, GIP and GLP-1. Our guide to GLP-1 vs GIP explains the difference.
Mazdutide clinical trial results
| Trial | Who | Weekly dose | Length | Main result |
|---|---|---|---|---|
| GLORY-1 (NEJM 2025) | 610 Chinese adults with overweight or obesity | 4 mg or 6 mg | 48 weeks | Weight down 11.0% and 14.0% vs a 0.3% gain on placebo |
| GLORY-2 (JAMA 2026) | 461 Chinese adults with BMI 30 or more | 9 mg | 60 weeks | Weight down 16.7% vs 1.5% on placebo |
| US phase 2 (Lancet Diabetes and Endocrinology 2026) | 179 US adults without diabetes | 3 to 6 mg, 10 mg, 16 mg | 48 weeks | At week 32: down 7.3%, 15.6% and 18.1% vs 0.9% on placebo |
| DREAMS-1 (Nature 2026) | 320 Chinese adults with type 2 diabetes | 4 mg or 6 mg | 24 weeks | HbA1c down 1.57 and 2.15 points vs 0.14 on placebo |
| DREAMS-3 (company release) | 349 Chinese adults with type 2 diabetes and obesity | 6 mg vs semaglutide 1 mg | 32 weeks | Weight down 10.3% vs 6.0% |
A few things to keep in mind when you read these numbers:
- The GLORY figures above count everyone, including people who stopped early. Innovent's own releases use a different method and quote higher figures, such as 18.55% for GLORY-2.
- In GLORY-1, about half of people on 6 mg (49.5%) lost at least 15% of their weight by week 48.
- DREAMS-3 compared mazdutide with semaglutide 1 mg, the diabetes dose. That is lower than the 2.4 mg in Wegovy. So it does not tell you that mazdutide beats Wegovy.
Mazdutide vs tirzepatide, semaglutide and retatrutide
No trial has put mazdutide against Zepbound, Wegovy or retatrutide. This table lines up separate trials, so use it as a rough map only.
| Drug | Targets | Status (Nov 2026) | Weight loss in its main trial |
|---|---|---|---|
| Mazdutide | Glucagon + GLP-1 | Approved in China only | About 17% at 60 weeks on 9 mg (GLORY-2) |
| Tirzepatide (Zepbound) | GIP + GLP-1 | FDA approved | 20.9% at 72 weeks on 15 mg (SURMOUNT-1) |
| Semaglutide (Wegovy) | GLP-1 | FDA approved | 14.9% at 68 weeks on 2.4 mg (STEP 1) |
| Retatrutide | GIP + GLP-1 + glucagon | Not approved | 28.3% at 80 weeks on 12 mg, if staying on (TRIUMPH-1) |
GLORY-2 ran for a shorter time than the others, and its volunteers were young, with a mean age of about 34. A head-to-head trial against semaglutide in people with fatty liver, called GLORY-3, is still running. For the approved pair, see semaglutide vs tirzepatide. For the triple agonist, see retatrutide vs semaglutide vs tirzepatide.
Mazdutide side effects
The common ones are the usual GLP-1 stomach problems, and at the 9 mg dose they were frequent. In GLORY-2:
- Vomiting: 53.1% on mazdutide vs 1.3% on placebo
- Nausea: 46.9% vs 3.2%
- Diarrhea: 39.4% vs 6.5%
Most cases were mild to moderate. Few people quit over them: 2.9% on mazdutide stopped because of side effects, and nobody on placebo did. In GLORY-1, the stop rate was 1.5% on 4 mg and 0.5% on 6 mg.
Higher doses were harder to take. In the US phase 2 trial, 20% of people on 16 mg stopped treatment because of side effects, mostly gut related.
Fast weight loss also costs some muscle on every drug in this class. We did not find lean mass results in the mazdutide papers and releases we read, so that question is open. What protects muscle is the same either way: enough protein and regular strength training. Sharpy sets one protein target and one 20-minute workout a day, and its Shape Score shows whether you are losing fat or muscle. Our guide to resistance training on GLP-1 covers the basics.
Mazdutide approval in China: what just changed
Innovent's release, dated November 13 and 14, 2026, says:
- Mazdutide is newly on China's National Reimbursement Drug List.
- The listing is for type 2 diabetes in adults. Weight management is not named.
- The updated list takes effect on January 1, 2027.
- No price was given.
So from January, people in China who take mazdutide for type 2 diabetes can have it covered by state insurance. People who take it for weight loss alone should expect to keep paying out of pocket.
A higher 9 mg dose for moderate to severe obesity is also in play. China's regulator accepted that application for review in November 2025. We did not find an approval announcement as of November 14, 2026. China's obesity market is moving fast: regulators there also just cleared orforglipron, Lilly's weight loss pill.
Mazdutide FDA approval: is it coming to the US?
Not soon, and maybe not at all. Here is what is confirmed:
- There is no FDA filing and no announced date for one.
- Lilly ran a US phase 2 obesity trial at 24 centers. It finished in 2025 and was published in 2026.
- No US phase 3 obesity trial is listed on ClinicalTrials.gov.
- Lilly already sells Zepbound and is far along with retatrutide, which also hits the glucagon receptor.
In China, Innovent is testing mazdutide in teens with obesity, sleep apnea, high blood pressure, fatty liver disease (MASH) and heart failure. Those trials are still running.
Mazdutide for alcohol use disorder
Many people search for this. Lilly ran a phase 2 trial of mazdutide against placebo in 308 people with alcohol use disorder in the United States. ClinicalTrials.gov lists it as completed in March 2026. We could not find published results. Until they are out, nobody can say whether it works. Our guide to GLP-1 for addiction covers what is known for the approved drugs.
Can you buy mazdutide peptide online?
Websites sell vials labeled "mazdutide peptide" for "research use." These are not the medicine tested in the trials. No regulator has checked what is in them, how strong they are or whether they are sterile. Please do not inject them. If you want a glucagon and GLP-1 drug, a clinical trial is the only legitimate route outside China. If you want proven weight loss now, talk to your prescriber about the approved options in our GLP-1 drugs list.
The bottom line
Mazdutide is a real, approved drug, but only in China. It is a weekly glucagon and GLP-1 shot with weight loss between Wegovy and Zepbound in separate trials, and a lot of nausea and vomiting at the 9 mg dose. China will cover it for type 2 diabetes from January 2027. A US launch is not on the calendar.
Whichever shot you use, the goal is to lose fat and keep muscle. Sharpy keeps that simple with one protein target, one short workout and one Shape Score each day.
Sources
- Innovent, November 13, 2026: Seven innovative products including mazdutide included in the 2026 National Reimbursement Drug List
- Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). N Engl J Med. 2025
- Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity (GLORY-2). JAMA. 2026
- Hsia SH, et al. Mazdutide in adults with obesity or overweight: US phase 2 trial. Lancet Diabetes Endocrinol. 2026
- Zhu D, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes (DREAMS-1). Nature. 2026
- Innovent, October 26, 2025: DREAMS-3 head-to-head trial vs semaglutide
- Innovent, June 27, 2025: Mazdutide approved by China's NMPA for chronic weight management
- Innovent, November 25, 2025: Mazdutide 9 mg application accepted for review
- ClinicalTrials.gov: mazdutide studies
Questions people ask
What is mazdutide used for?
In China, mazdutide is approved for long-term weight management in adults with obesity, or with overweight plus a weight-related health problem, and for blood sugar control in adults with type 2 diabetes. It is not approved for any use in the United States or Europe.
Is mazdutide FDA approved?
No. Mazdutide has no FDA approval and no FDA filing has been announced. Eli Lilly has run a US phase 2 obesity trial, published in 2026, but has not announced a phase 3 program for US approval. China is the only country where it is approved.
Is mazdutide a peptide?
Yes. Mazdutide is a peptide drug modeled on a natural gut hormone called oxyntomodulin. It is given as a shot under the skin once a week. Vials sold online as "mazdutide peptide" are not the approved medicine and have not been checked by any regulator.
How does mazdutide compare with tirzepatide?
They have not been tested head to head. Tirzepatide (Zepbound) acts on GIP and GLP-1 and led to 20.9% weight loss at 72 weeks on 15 mg in SURMOUNT-1. Mazdutide acts on glucagon and GLP-1 and led to about 17% at 60 weeks on 9 mg in GLORY-2. The trials differ in length, dose and population.
What are mazdutide side effects?
Mostly stomach and gut problems. In the GLORY-2 trial of the 9 mg dose, 53.1% of people had vomiting, 46.9% had nausea and 39.4% had diarrhea. Most cases were mild to moderate, and 2.9% of people stopped the drug because of side effects.
Who makes mazdutide, Eli Lilly or Innovent?
Both are involved. Eli Lilly first developed it (code name LY3305677, also called OXM3). Innovent Biologics licensed the rights for China, where its code name is IBI362, and ran the trials that led to approval there. Lilly has run its own studies in the United States.
Does mazdutide help with alcohol use disorder?
That is not known yet. Lilly ran a phase 2 trial of mazdutide against placebo in 308 people with alcohol use disorder. ClinicalTrials.gov lists it as completed in March 2026. We could not find published results, so there is nothing solid to report.